Corrigendum: STAT5a Confers Doxorubicin Resistance to Breast Cancer by Regulating ABCB1(Front. Oncol., (2021), 11, (697950), 10.3389/fonc.2021.697950)

doi:10.3389/fonc.2022.880458

科研成果详情

名称	Corrigendum: STAT5a Confers Doxorubicin Resistance to Breast Cancer by Regulating ABCB1(Front. Oncol., (2021), 11, (697950), 10.3389/fonc.2021.697950)
作者	Li, Zhaoqing 1,2,3,4; Chen, Cong 2,3,4; Chen, Lini 2,3,4; Hu, Dengdi 2,3,4,5; Yang, Xiqian 2,3,4,6; Zhuo, Wenying 2,3,4,5; Chen, Yongxia 2,3,4; Yang, Jingjing 2,3,4; Zhou, Yulu 2,3,4; Mao, Misha 2,3,4; Zhang, Xun 2,3,4; Xu, Ling 2,3,4; Ju, Siwei 2,3,4; Shen, Jun 2,3,4; Wang, Qinchuan 2,3,4; Dong, Minjun 2,3,4; Xie, Shuduo 2,3,4; Wei, Qun 2,3,4; Jia, Yunlu 7; Zhou, Jichun 2,3,4; Wang, Linbo 2,3,4
发表期刊	Frontiers in Oncology;
语种	英语
原始文献类型	Erratum
关键词	ABCB1 breast cancer doxorubicin resistance pimozide STAT5A
摘要	In the original article, there was a mistake in Figure 1 as published. In Figure 1F, the number “42” should be “38”. The corrected Figure 1 appears below. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
出版者	FRONTIERS MEDIA SA
ISSN	2234-943X
卷号	12
DOI	10.3389/fonc.2022.880458
页数	2
WOS类目	Oncology
WOS研究方向	Oncology
WOS记录号	WOS:000784070100001
收录类别	SCOPUS ; SCIE
发布日期	2022-03-09
URL	查看原文
PubMed ID	35356217
通讯作者地址	[Zhou, Jichun;Wang, Linbo]Zhejiang Univ, Sir Run Run Shaw Hosp, Hangzhou, Peoples R China. ; [Zhou, Jichun;Wang, Linbo]Biomed Res Ctr, Hangzhou, Peoples R China. ; [Zhou, Jichun;Wang, Linbo]Key Lab Biotherapy Zhejiang Prov, Hangzhou, Peoples R China.
Scopus学科分类	Oncology;Cancer Research
SCOPUSEID	SCOPUS_ID:85136366867
引用统计
文献类型	其他
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/184783
专题	其他_附属慈溪医院（慈溪市人民医院）
通讯作者	Zhou, Jichun; Wang, Linbo
作者单位	1.Zhejiang Univ, Canc Inst, Sch Med,China Natl Minist Educ, Key Lab Canc Prevent & Intervent,Affilated Hosp 2, Hangzhou, Peoples R China; 2.Zhejiang Univ, Sir Run Run Shaw Hosp, Hangzhou, Peoples R China; 3.Biomed Res Ctr, Hangzhou, Peoples R China; 4.Key Lab Biotherapy Zhejiang Prov, Hangzhou, Peoples R China; 5.Wenzhou Med Univ, Affiliated Cixi Hosp, Ningbo, Peoples R China; 6.Shaoxing Matern & Child Hlth Care Hosp, Breast Surg Dept, Shaoxing, Peoples R China; 7.Zhejiang Univ, Affiliated Hosp 1, Sch Med, Hangzhou, Peoples R China
推荐引用方式 GB/T 7714	Li, Zhaoqing,Chen, Cong,Chen, Lini,et al. Corrigendum: STAT5a Confers Doxorubicin Resistance to Breast Cancer by Regulating ABCB1(Front. Oncol., (2021), 11, (697950), 10.3389/fonc.2021.697950). 2022.